These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 22531163)
1. Fibroblast growth factor 23 and the heart. Faul C Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):369-75. PubMed ID: 22531163 [TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 and the future of phosphorus management. Wolf M Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):463-8. PubMed ID: 19770756 [TBL] [Abstract][Full Text] [Related]
3. FGF23 and Klotho in chronic kidney disease. Olauson H; Larsson TE Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):397-404. PubMed ID: 23666415 [TBL] [Abstract][Full Text] [Related]
4. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk. Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672 [TBL] [Abstract][Full Text] [Related]
5. What would we like to know, and what do we not know about fibroblast growth factor 23? Cozzolino M; Galassi A; Apetrii M; Covic A J Nephrol; 2011; 24(6):696-706. PubMed ID: 21786227 [TBL] [Abstract][Full Text] [Related]
6. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. Nakai K; Komaba H; Fukagawa M J Nephrol; 2010; 23(6):619-25. PubMed ID: 20658451 [TBL] [Abstract][Full Text] [Related]
7. FGF23: a mature renal and cardiovascular risk factor? Zoccali C; Yilmaz MI; Mallamaci F Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695 [TBL] [Abstract][Full Text] [Related]
8. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Heine GH; Seiler S; Fliser D Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630 [TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. Fliser D; Kollerits B; Neyer U; Ankerst DP; Lhotta K; Lingenhel A; Ritz E; Kronenberg F; ; Kuen E; König P; Kraatz G; Mann JF; Müller GA; Köhler H; Riegler P J Am Soc Nephrol; 2007 Sep; 18(9):2600-8. PubMed ID: 17656479 [TBL] [Abstract][Full Text] [Related]
10. FGF23/FGFR4-mediated left ventricular hypertrophy is reversible. Grabner A; Schramm K; Silswal N; Hendrix M; Yanucil C; Czaya B; Singh S; Wolf M; Hermann S; Stypmann J; Di Marco GS; Brand M; Wacker MJ; Faul C Sci Rep; 2017 May; 7(1):1993. PubMed ID: 28512310 [TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis. Gutiérrez OM Clin J Am Soc Nephrol; 2010 Sep; 5(9):1710-6. PubMed ID: 20507957 [TBL] [Abstract][Full Text] [Related]
12. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731 [TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Isakova T Curr Opin Nephrol Hypertens; 2012 May; 21(3):334-40. PubMed ID: 22487610 [TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 23 (FGF23) induces ventricular arrhythmias and prolongs QTc interval in mice in an FGF receptor 4-dependent manner. Graves JM; Vallejo JA; Hamill CS; Wang D; Ahuja R; Patel S; Faul C; Wacker MJ Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2283-H2294. PubMed ID: 33929896 [TBL] [Abstract][Full Text] [Related]